Public Employees Retirement System of Ohio lessened its holdings in shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) by 7.4% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 44,278 shares of the biotechnology company’s stock after selling 3,531 shares during the period. Public Employees Retirement System of Ohio’s holdings in Sarepta Therapeutics were worth $4,832,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. SG Americas Securities LLC acquired a new position in shares of Sarepta Therapeutics in the 3rd quarter valued at $242,000. Bank of New York Mellon Corp grew its holdings in shares of Sarepta Therapeutics by 1.3% in the 3rd quarter. Bank of New York Mellon Corp now owns 278,845 shares of the biotechnology company’s stock valued at $45,036,000 after buying an additional 3,537 shares during the period. Korea Investment CORP acquired a new position in shares of Sarepta Therapeutics in the 3rd quarter valued at $3,295,000. FDx Advisors Inc. bought a new stake in Sarepta Therapeutics in the 3rd quarter valued at $249,000. Finally, Dimensional Fund Advisors LP lifted its position in Sarepta Therapeutics by 1.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 155,442 shares of the biotechnology company’s stock valued at $25,102,000 after acquiring an additional 2,742 shares in the last quarter. 95.66% of the stock is owned by hedge funds and other institutional investors.
Shares of NASDAQ:SRPT opened at $122.68 on Thursday. The company has a current ratio of 8.21, a quick ratio of 7.49 and a debt-to-equity ratio of 0.41. Sarepta Therapeutics Inc has a one year low of $70.50 and a one year high of $176.50. The stock has a market cap of $8.75 billion, a price-to-earnings ratio of -22.47 and a beta of 2.04.
Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, February 27th. The biotechnology company reported ($0.85) EPS for the quarter, topping the consensus estimate of ($1.08) by $0.23. Sarepta Therapeutics had a negative net margin of 120.22% and a negative return on equity of 36.73%. The firm had revenue of $84.40 million for the quarter, compared to analysts’ expectations of $84.83 million. During the same period in the previous year, the firm posted ($0.37) EPS. The company’s revenue for the quarter was up 47.3% on a year-over-year basis. As a group, equities analysts forecast that Sarepta Therapeutics Inc will post -4.71 EPS for the current fiscal year.
Several research firms recently commented on SRPT. Cowen reaffirmed a “buy” rating and issued a $213.00 price objective on shares of Sarepta Therapeutics in a research report on Sunday. Credit Suisse Group reaffirmed an “outperform” rating and issued a $207.00 price objective (up from $189.00) on shares of Sarepta Therapeutics in a research report on Monday, March 11th. Citigroup boosted their price objective on shares of Sarepta Therapeutics from $188.00 to $201.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Janney Montgomery Scott set a $200.00 price objective on shares of Sarepta Therapeutics and gave the company a “buy” rating in a research report on Tuesday, January 8th. Finally, Nomura boosted their price objective on shares of Sarepta Therapeutics from $205.00 to $230.00 and gave the company a “buy” rating in a research report on Thursday, February 28th. One analyst has rated the stock with a sell rating, three have given a hold rating, twenty-five have issued a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $191.90.
In other news, CFO Sandesh Mahatme sold 65,000 shares of the company’s stock in a transaction dated Thursday, January 31st. The shares were sold at an average price of $130.23, for a total value of $8,464,950.00. Following the sale, the chief financial officer now directly owns 14,118 shares of the company’s stock, valued at approximately $1,838,587.14. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP David T. Howton sold 30,000 shares of the company’s stock in a transaction dated Friday, February 1st. The shares were sold at an average price of $140.00, for a total transaction of $4,200,000.00. Following the completion of the sale, the senior vice president now directly owns 31,196 shares in the company, valued at $4,367,440. The disclosure for this sale can be found here. Insiders have sold a total of 160,000 shares of company stock worth $22,089,950 over the last three months. Insiders own 7.90% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Public Employees Retirement System of Ohio Has $4.83 Million Holdings in Sarepta Therapeutics Inc (SRPT)” was originally posted by Zolmax and is the sole property of of Zolmax. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://zolmax.com/investing/public-employees-retirement-system-of-ohio-has-4-83-million-holdings-in-sarepta-therapeutics-inc-srpt/3014018.html.
Sarepta Therapeutics Profile
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.
Further Reading: How are the companies in the S&P 500 selected?
Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics Inc (NASDAQ:SRPT).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.